Marker Therapeutics, Inc. (GX1.MU)

4.2200 0.0000 (0.00%) 收市：08:09AM CEST

Marker Therapeutics, Inc.

9350 Kirby Drive
Suite 300
Houston, TX 77054
United States
713 400 6400
https://markertherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 8

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Juan F. Vera M.D.	Co-Founder, CEO, President, Treasurer, Secretary & Director	372.01k	無	1980
Ms. Elizabeth Donnelly	Director of Administration	無	無	無
Dr. Maria-Bernadette Madel	Director of Corporate Operations & External Communications	無	無	1990
Mr. Edmund Cheung	Vice President of Human Resources	無	無	無
Dr. Nadia Agopyan Ph.D.	Senior Vice President of Regulatory Affairs	無	無	無
Dr. Monic Stuart M.D.	Chief Medical Officer	無	無	無
Patricia Allison	Head of Clinical Operations	無	無	無
Dr. Robert Z. Florkiewicz Sr.	Senior Director of Molecular Biology & Virology	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

公司管治

截至 無 止，Marker Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。